MedDay Pharmaceuticals

Jesús Martin-Garcia, founder and CEO of Geneva-based GeNeuro SA , is a man on a mission. He has been forging a clinical path for what would become the monoclonal antibody temelimab (previously known

Pan-EU marketing authorization is all but guaranteed for the seven products that this week received the thumbs up from the European Medicines Agency’s key scientific committee, the CHMP. The initial m

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Roche 's is embarking upon a brave pricing strategy for its new multiple sclerosis drug Ocrevus (ocrelizumab) now that it has finally been licensed by the US FDA, following a slight technical hitch